← The library
FDA-approved

Tirzepatide

aka Mounjaro, Zepbound

Hits two appetite-and-insulin hormones at once. Sold as Mounjaro and Zepbound.

Technically · Dual agonist (GLP-1 + GIP)

weight lossfat loss
Mounjaro
The vial
Tirzepatide 2D molecular structure
The moleculeCID 156588324

In one sentence

The most powerful FDA-approved weight-loss shot — up to 22.5% weight loss at the top dose.

Ozempic's upgraded twin — hits one more receptor (GIP) for stronger appetite control.

Half-life

~5 days

Stays active about 5 days — one shot per week.

Dosing

Once weekly

How often you take a dose

Route

SubQ

How it goes into the body

Status

FDA

Approved by the FDA for prescription use

Education only. Many compounds discussed are research chemicals not approved for human use in the US. This is not medical advice — consult a licensed physician.

What it is

The most powerful weight-loss drug the FDA has approved. It mimics two of your gut hormones (GLP-1 and GIP) to crush appetite, slow your stomach down, and steady your blood sugar. In its trial, top dose lost 22.5% body weight in just over a year.

The full technical answer

FDA-approved dual GLP-1/GIP agonist marketed as Mounjaro (T2D) and Zepbound (obesity). Outperforms semaglutide on weight loss in head-to-head trials.

How it works

After you eat, your gut releases GLP-1 and GIP — they signal "you're full, sugar is handled." Tirzepatide is a synthetic version of those signals but stronger and longer-lasting. Result: smaller portions feel satisfying, cravings fade, and your body manages food more efficiently.

The full technical answer

Activates both GLP-1 and GIP receptors. Suppresses appetite, slows gastric emptying, enhances glucose-dependent insulin secretion.

ExtracellularInside the cellGLP-1ReceptorGIPReceptorpeptidedownstream signaling
Receptors hit: GLP-1, GIP. The peptide binds the receptor on the cell surface, triggering downstream signaling inside the cell.

What the research says

SURMOUNT-1 trial showed up to 22.5% weight loss at 72 weeks at 15mg weekly.

Sources: NEJM SURMOUNT-1 · FDA label (Zepbound)

Common dosing ranges

Range
Start 2.5 mg/week, titrate to 15 mg/week max per FDA label
Frequency
Once weekly
Duration
Long-term per FDA label

Sources: FDA Zepbound label

How to take it

Practical guidance synthesized from clinical protocols, FDA labels, and clinician interviews. Always cross-check with a prescribing physician.

Best time of day

Once a week, any day, any time of day per FDA label. Pick a day you'll remember (most people pick Sunday).

With food or fasted

With or without — doesn't affect the drug. Eat lighter, lower-fat meals the first few days after injection to reduce nausea.

How long to cycle

Long-term per FDA label. Titrate every 4 weeks: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg.

When to get off

Severe abdominal pain, persistent vomiting, or a new neck lump → stop and call a doctor immediately. Don't push past a dose step that causes lasting side effects.

Administration

SubQ

Side effects

Common

  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Abdominal pain

Serious / theoretical

  • Pancreatitis
  • Gallbladder disease
  • Thyroid C-cell tumor warning

Sources: FDA label

Often compared